Gilead Sciences (GILD) Total Non-Current Liabilities (2009 - 2026)

Gilead Sciences has reported Total Non-Current Liabilities for 18 years, with the latest figure at $31.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 12.37% year-over-year to $31.6 billion; the trailing twelve-month figure through Mar 2026 stood at $31.6 billion (down 12.37% YoY), and the FY2025 full-year result was $35.4 billion, down 8.98% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $31.6 billion, down from $35.4 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $42.2 billion in Q1 2022, with the low at $31.6 billion in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $37.5 billion across 5 years, with a median of $37.4 billion in 2024.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities decreased 14.85% — and 2025, when it gained 3.85%.
• Gilead Sciences' Total Non-Current Liabilities stood at $40.8 billion in 2022, then slipped by 6.59% to $38.1 billion in 2023, then increased by 2.16% to $38.9 billion in 2024, then decreased by 8.98% to $35.4 billion in 2025, then fell by 10.9% to $31.6 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $31.6 billion (Q1 2026), $35.4 billion (Q4 2025), and $35.8 billion (Q3 2025), per Business Quant data.